✦ LIBER ✦

584 Long-term low dose treatment with pegylated interferon α-2b leads to a significant reduction in fibrosis in chronic hepatitis C nonresponder patients

✍ Scribed by S. Kaiser; H. Hass; B. Lutze; M. Gregor

Book ID: 117374860
Publisher: Elsevier Science
Year: 2006
Tongue: English
Weight: 123 KB
Volume: 44
Category: Article
ISSN: 0168-8278
DOI: 10.1016/s0168-8278(06)80584-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Long term response to interferon treatme

Long term response to interferon treatment in chronic hepatitis C patients is associated with a significant reduction in anti-E1 envelope antibody titers

✍ Depraetere, Stany; Van Kerschaever, Els; Van Vlierberghe, Hans; Elewaut, Andr�; 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 101 KB 👁 2 views

Interferon (IFN) alfa has been used widely for the treatment of chronic hepatitis C virus (HCV) infections but only a small number of patients treated have shown a sustained biochemical and virological response. Anti-envelope E1 and E2 antibody titers were assessed retrospectively before, during, an

Long-term treatment with low doses of in

Long-term treatment with low doses of interferon ALFA-2B (rIFNa2b) in patients with chronic non-A, non-B (NANB) hepatitis: Data of a multicenter randomized prospectively controlled trial

✍ Müller, R.; Baumgarten, R.; Markus, R.; Beckh, K.H.; Loeschke, K.; Stremmel, W.; 📂 Article 📅 1990 🏛 Elsevier Science 🌐 English ⚖ 107 KB

Pegylated interferon alpha-2b (Peg-IFN α

Pegylated interferon alpha-2b (Peg-IFN α-2b) affects early virologic response dose-dependently in patients with chronic hepatitis C genotype 1 during treatment with Peg-IFN α-2b plus ribavirin

✍ T. Oze; N. Hiramatsu; T. Yakushijin; M. Kurokawa; T. Igura; K. Mochizuki; K. Ima 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 175 KB